Millions Share a Deadly Genetic Heart Risk. This Experimental Drug Could Be a Game Changer
An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease. In clinical trial data published over the weekend, Eli Lilly’s lepodisiran was found to dramatically reduce people’s levels of a dangerous kind of cholesterol called lipoprotein (a), or Lp (a).
Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...
Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, ...
Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...
Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...
CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback